

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 October 2023 (12.10.2023)



(10) International Publication Number
WO 2023/194528 A1

(51) International Patent Classification:

A61K 31/4155 (2006.01) A61P 35/00 (2006.01)
A61K 31/4375 (2006.01) A61P 35/04 (2006.01)
A61K 9/00 (2006.01)

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2023/059126

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(22) International Filing Date:

06 April 2023 (06.04.2023)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/362,612 07 April 2022 (07.04.2022) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; 151 85
Södertälje (SE).

(72) Inventors: **COSULICH, Sabina Chiara**; AS-
TRAZENECA UK LIMITED, 1 Francis Crick Av-
enue, Cambridge Biomedical Campus, Cambridge, Cam-
bridgeshire CB2 0AA (GB). **BROWN, Jessica S**; AS-
TRAZENECA UK LIMITED, 1 Francis Crick Av-
enue, Cambridge Biomedical Campus, Cambridge, Cam-
bridgeshire CB2 0AA (GB). **ALBERTELLA, Mark R**;
ASTRAZENECA UK LIMITED, 1 Francis Crick Av-
enue, Cambridge Biomedical Campus, Cambridge, Cam-
bridgeshire CB2 0AA (GB). **LEO, Elisabetta**; AS-
TRAZENECA UK LIMITED, 1 Francis Crick Av-
enue, Cambridge Biomedical Campus, Cambridge, Cam-
bridgeshire CB2 0AA (GB).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-
TY**; Association 813, Eastbrook House, Shaftesbury Road,
CAMBRIDGE, Cambridgeshire CB2 8BF (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: COMBINATION THERAPY FOR TREATING CANCER

(57) Abstract: The present disclosure includes methods, pharmaceutical compositions, and kits for the treatment of prostate cancer, wherein AZD5305 and darolutamide are dosed in combination to a subject in need.



WO 2023/194528 A1